These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 21593172)

  • 1. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
    Denton PW; Othieno F; Martinez-Torres F; Zou W; Krisko JF; Fleming E; Zein S; Powell DA; Wahl A; Kwak YT; Welch BD; Kay MS; Payne DA; Gallay P; Appella E; Estes JD; Lu M; Garcia JV
    J Virol; 2011 Aug; 85(15):7582-93. PubMed ID: 21593172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
    Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
    PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
    Denton PW; Krisko JF; Powell DA; Mathias M; Kwak YT; Martinez-Torres F; Zou W; Payne DA; Estes JD; Garcia JV
    PLoS One; 2010 Jan; 5(1):e8829. PubMed ID: 20098623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
    Celum C; Baeten JM
    Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.
    Gallay PA; Chatterji U; Kirchhoff A; Gandarilla A; Gunawardana M; Pyles RB; Marzinke MA; Moss JA; Baum MM
    PLoS One; 2017; 12(9):e0184303. PubMed ID: 28880948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
    J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
    Moss JA; Srinivasan P; Smith TJ; Butkyavichene I; Lopez G; Brooks AA; Martin A; Dinh CT; Smith JM; Baum MM
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
    Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.
    Chateau ML; Denton PW; Swanson MD; McGowan I; Garcia JV
    PLoS One; 2013; 8(3):e60024. PubMed ID: 23527295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
    Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
    J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
    Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
    Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
    Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
    Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
    Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.
    Gengiah TN; Baxter C; Mansoor LE; Kharsany AB; Abdool Karim SS
    Expert Opin Investig Drugs; 2012 May; 21(5):695-715. PubMed ID: 22394224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection.
    Olesen R; Wahl A; Denton PW; Garcia JV
    J Reprod Immunol; 2011 Mar; 88(2):195-203. PubMed ID: 21256601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A perspective on progress and gaps in HIV prevention science.
    Kiser PF; Mesquita PM; Herold BC
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1373-8. PubMed ID: 22966871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.